Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-05-08
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 48
- Registration Number
- NCT00221312
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 120
- Registration Number
- NCT00177619
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Bisphosphonate Therapy for Osteogenesis Imperfecta
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT00159419
Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-23
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 56
- Registration Number
- NCT00157690
- Locations
- 🇨🇦
Dr. Harvey Rabin - Health Sciences Centre, Calgary, Alberta, Canada
🇨🇦Montreal Chest Institute, Montreal, Quebec, Canada
🇨🇦Centre de Recherche - CHUM, Montreal, Quebec, Canada
Texture Analysis for Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT00145977
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2011-12-22
- Target Recruit Count
- 140
- Registration Number
- NCT00120757
- Locations
- 🇫🇷
Hôpital Necker service des Maladies Infectieuses, Paris, France
🇫🇷Service de Medecine Interne hopital Avicenne, Bobigny, France
🇫🇷Service de Rhumatologie hopital Pitie-Salpetriere, Paris, France
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1053
- Registration Number
- NCT00092014
The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients
- Conditions
- First Posted Date
- 2003-05-23
- Last Posted Date
- 2009-08-07
- Target Recruit Count
- 80
- Registration Number
- NCT00061256
- Locations
- 🇺🇸
Stanford Univ, Stanford, California, United States
🇺🇸Chelsea Clinic, New York, New York, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
Prevention of Osteoporosis in Men With Prostate Cancer
- Conditions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 112
- Registration Number
- NCT00048841
- Locations
- 🇺🇸
Osteoporosis Prevention & Treatment Center, Pittsburgh, Pennsylvania, United States
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2002-08-07
- Last Posted Date
- 2013-09-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 412
- Registration Number
- NCT00043186
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.